pharmaceuticals PM market analysis — 2026-08-25

The clearest read-through this session is regulatory rather than commercial. Eli Lilly’s Foundayo has received FDA clearance for obesity, arriving alongside a period of strong quarterly results for the company, while Summit Therapeutics reported an overall survival benefit for ivonescimab in a lung cancer trial. Bristol-Myers Squibb also secured approval for Zenbexus, a cereblon-modulating protein degrader for multiple myeloma, adding to a run of concrete oncology and metabolic-disease clearances this month.

Set against that, pricing and distribution remain a source of friction. The FTC’s antitrust suit against pharmacy benefit managers, including Optum Rx and Express Scripts, keeps scrutiny on how drug costs are set and passed through the supply chain, a dynamic that tends to weigh on sentiment even when clinical news is favourable.

Coverage of data science and AI in drug development continues, framing machine learning as central to the discovery-to-trial pipeline, but this remains commentary and forward-looking discussion rather than a near-term catalyst. Taken together, the approvals and survival data support a constructive near-term picture for the companies involved, while PBM litigation and the still-aspirational tone of the AI coverage argue against reading the sector as uniformly bullish.